Market News & Trends
Breakthrough Study From UCLA Demonstrates Can-Fite’s Piclidenoson as a Treatment for Vascular Dementia
Can-Fite BioPharma Ltd. recently announced a leading group from University of Los Angeles (UCLA) demonstrates that Piclidenoson showed efficacy in an experimental model of vascular…
LENZ Therapeutics Announces NMPA Submission of ND for LNZ100 for Presbyopia Treatment
LENZ Therapeutics, Inc. recently announced CORXEL Pharmaceuticals has submitted the New Drug Application (NDA) for LNZ100 to the Center for Drug Evaluation (CDE) of the…
Radiopharm Theranostics Receives IND Approval to Initiate Phase 1 Therapeutic Clinical Study to Target B7H3 With Betabart
Radiopharm Theranostics recently announced the US FDA has provided clearance of the Company’s Investigational New Drug (IND) application for Betabart (RV-01), its Lu177-B7H3 monoclonal antibody…
Deciphera Announces Positive CHMP Opinion for ROMVIMZA for the Treatment of Tenosynovial Giant Cell Tumor
Deciphera Pharmaceuticals, LLC and Ono Pharmaceutical Co., Ltd. recently announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a…
Inmagene Biopharmaceuticals Announces Completion of Merger With Ikena Oncology & Concurrent Private Placement of $75 Million
Inmagene Biopharmaceuticals recently announced the completion of its previously announced merger with Ikena Oncology, Inc. The combined company will operate under the name ImageneBio, Inc.…
Simtra BioPharma Solutions Announces Strategic Purchase to Expand US Manufacturing Capacity for Injectable Medicines
Simtra BioPharma Solutions recently announced the purchase from Cook Group of a 65-acre property (301 N. Curry Pike) with more than 300,000 square feet of…
Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer
Candel Therapeutics, Inc. recently announced the European Medicines Agency (EMA) has granted Orphan Designation for CAN-2409 (aglatimagene besadenovec) for the treatment of pancreatic cancer. This…
Rheumatologists Eye AbbVie’s Rinvoq, Roche/Genentech’s Gazyva & Bristol Myers Squibb’s Sotyktu as Front-Runners to Address Persistent Gaps in Systemic Lupus Erythematosus Care
Biologic use in systemic lupus erythematosus (SLE) is steadily rising, with US rheumatologists now treating close to 40% of their moderate-to-severe patients with biologics. Most…
Jupiter Neurosciences Highlights Critical Advancement of JOTROL Over Traditional Resveratrol With Breakthrough Bioavailability & CNS-Targeted Science
Jupiter Neurosciences, Inc. spotlights the scientific and clinical advantages of its proprietary resveratrol platform, JOTROL, over conventional resveratrol formulations. Resveratrol is one of the world’s most…
Roquette Unveils POLYOX ES Packaging to Advance Excipient Stability & Sustainability
Roquette has recently launched POLYOX Extended Stability (ES) packaging, a customer-driven innovation that delivers measurable improvements in excipient stability, handling, and environmental impact. POLYOX Water…
BD Announces First Pharma-Sponsored Clinical Trial Using BD Libertas Wearable Injector Technology for Biologic Drugs
BD (Becton, Dickinson and Company) recently announced the first pharma-sponsored combination product clinical trial using the BD Libertas Wearable Injector for subcutaneous delivery of complex…
Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Delpacibart Zotadirsen (del-zota) for the Treatment of DMD in People with Mutations Amenable to Exon 44 Skipping
Avidity Biosciences, Inc. recently announced the US FDA has granted Breakthrough Therapy designation to delpacibart zotadirsen (del-zota) for the treatment of Duchenne muscular dystrophy (DMD)…
Leriglitazone Marketing Authorization Application Submitted for Treatment of Cerebral Adrenoleukodystrophy Has Been Validated by EMA
Minoryx Therapeutics and Neuraxpharm Group recently announced the Marketing Authorization Application (MAA) for Minoryx’s lead candidate leriglitazone (NEZGLYAL) has been submitted to the European Medicines…
Inotrem Unveils Game-Changing Precision Medicine Strategy for Nangibotide Clinical Development
Inotrem recently announced the publication of its precision medicine strategy for its leading drug candidate nangibotide, a first-in-class TREM-1 inhibitor in septic shock. This work…
Polyrizon Reports Successful Intranasal Delivery of PL-14 Allergy Blocker in Latest Study
Polyrizon Ltd. recently announced encouraging preclinical results supporting the performance of its PL-14 Allergy Blocker, part of its proprietary Capture & Contain (C&C) platform. The…
Arch Biopartners Announces Start of Patient Recruitment in Phase 2 Trial Targeting Drug-Toxin-Related Acute Kidney Injury
Arch Biopartners Inc. recently announced the investigator-led Phase 2 trial titled Prevention Of NephroToxin Induced Acute Kidney Injury with Cilastatin (PONTIAK) has commenced patient recruitment…
etherna Achieves Major Milestones in its Bio-Reducible LNP Platform
etherna immunotherapies NV recently announced breakthrough innovation in efficient in vivo extrahepatic delivery of mRNA to several key tissues, including to hematopoietic and progenitor stem…
Abzena Appoints Geoffrey M. Glass as Chief Executive Officer
[caption id="attachment_146338" align="alignleft" width="160"] Geoffrey M. Glass[/caption] Abzena, a leading end-to-end integrated CDMO + CRO for complex biologics and bioconjugates, recently announced Geoffrey M. Glass…
Nemera Expands Production Capacity in Szczecin to Strengthen Leadership in GLP-1 Drug Market
Nemera, a global leader in the design, development, and manufacturing of drug delivery device solutions, has inaugurated a new production hall at its state-of-the-art facility…
Monte Rosa Therapeutics Announces First Subjects Dosed in Phase 1 Study of a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Monte Rosa Therapeutics, Inc. recently announced the first subjects have been dosed in a Phase 1 study evaluating MRT-8102, a NEK7-directed MGD being developed for…
